BridgeMD
New treatment option for NSTEMI - Non-ST Segment Elevation MI
Official title Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
ClinicalTrials.gov ID: NCT07257198
What this study is testing
What is Ticagrelor + aspirin?
Ticagrelor + aspirin is an investigational medicine, given as an once-daily, being studied as a potential treatment for nstemi - non-st segment elevation mi.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- In patients with a myocardial infarction (MI) treated medically alone, the objective of the PANTHEON trial is to evaluate if ticagrelor monotherapy reduces bleeding events, without an increase in patient-oriented ischemic events, compared with standard dual antiplatelet therapy (DAPT) with aspirin and ticagrelor for 12 months.
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥18 years;
- Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;
- Coronary angiogram performed;
- Planned for medical management alone, without revascularization;
- Willingness to participate and to attend study visits;
You likely can't join if
- Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;
- Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;
- Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury...
- Confirmed or suspected spontaneous coronary artery dissection;
- Concomitant indication for chronic oral anticoagulant;
- Concomitant non-coronary indication for dual antiplatelet therapy;
See the full eligibility criteria
- Age ≥18 years;
- Hospitalized for type 1 MI, according to the 4th Universal Definition of MI;
- Coronary angiogram performed;
- Planned for medical management alone, without revascularization;
- Willingness to participate and to attend study visits;
- Expected life expectancy ≥12 months.
- Patients hospitalized for type 2-5 MI, or unstable angina, according to the 4th Universal Definition of MI;
- Patients hospitalized for a STEMI with an acute thrombotic lesion of a major epicardial vessel;
- Elevations in cardiac biomarkers (troponins or CK-MB) that is believed by the investigator not to be of ischemic origin (e.g. myocardial injury, myocarditis, Takotsubo syndrome, etc.);
- Confirmed or suspected spontaneous coronary artery dissection;
- Concomitant indication for chronic oral anticoagulant;
- Concomitant non-coronary indication for dual antiplatelet therapy;
- Use of any non-trial antiplatelet drug that needs to be continued based on the judgement of the treating physician;
- Previous hospitalization for MI, PCI, or CABG within 12 months;
- Known hypersensitivity, intolerance, or contra-indication to ASA or ticagrelor;
- Unsuitability for either randomization treatment, based on the judgement of the treating physician
The study team makes the final eligibility decision.
Where it's taking place
- Montreal, Quebec, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Montreal, Quebec, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.